Preconception GLP
Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy , gestational diabetes, have a preterm birth or cesarean ...
The prescription of glucagon-like peptide-1 receptor agonist within 24 months preceding a pregnancy was associated with a reduced risk of several adverse obstetrical outcomes, including gestational diabetes mellitus, hypertensive disorders of pregnancy , preterm delivery, and cesarean delivery. This suggests that the use of glucagon-like peptide-1 receptor agonists may be a powerful tool to ...
Key Details About Preconception Glp 1 Receptor Agonist Use May Reduce Pregnancy Risks
Obesity in reproductive-age women is associated with increased risk of cardiometabolic disease, infertility, and pregnancy -related complications affecting both the mother and fetus. Recently, the introduction of highly effective glucagon-like peptide-1 ( GLP-1 ) receptor agonists has led to increased utilization of obesity medications in this population. While these agents are not recommended ...
Current evidence suggests that preconceptional or early- pregnancy exposure to GLP-1-based therapies is not consistently associated with increased maternal, fetal, or neonatal risk , although data on continued use throughout gestation remain limited.
Useful Notes on Preconception Glp 1 Receptor Agonist Use May Reduce Pregnancy Risks
Abstract Aim: To evaluate the association between preconception glucagon-like peptide-1 receptor agonist ( GLP -1RA)/tirzepatide use and the risk of gestational diabetes mellitus (GDM). Methods: This retrospective cohort study (January 1 , 2015-April 30, 2025) utilised the TriNetX multinational network.
In summary, GLP-1 RA exposure in pregnancy may be associated with improvement in maternal outcomes and a lower observed risk of preterm births, without a detectable increase in congenital malformations.
Preconception GLP
Women of reproductive age are increasingly prescribed GLP-1 drugs for weight-management support, but the risks and benefits of using these medications before pregnancy is still poorly understood. Recent research by Cleveland Clinic physicians finds that taking GLP-1 drugs before conception does not increase the risks for adverse pregnancy outcomes and might even provide some protection.
Human studies reporting exposure to GLP-1 or dual GLP-1/GIP receptor agonists during preconception , pregnancy , or lactation were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using validated tools.
Preconception use of GLP
This narrative review examines the current human evidence on GLP-1 and dual GLP-1/GIP receptor agonists approved for obesity treatment, focusing on their potential role in preconception care and addressing key safety considerations and challenges related to their use during the preconception period, as well as inadvertent exposure in early ...
Glucagon-like peptide-1 receptor agonists are peptide analogues that are used to treat type 2 diabetes mellitus and obesity. The first medication in this class, exenatide, was approved in 2005, and these medications, specifically semaglutide, have become more popular in recent years due to their pronounced effects on glycemic control, weight reduction, and cardiovascular health. Due to ...